COVID-19’s Impact on the Digital Transformation of Clinical Trials

August 28, 2020
Oracle Health Sciences

Sponsored Content

COVID-19 has accelerated digital transformation roadmaps at sponsors and CROs, as well as, the adoption of new innovation strategies to respond to the realities of shelter-in-place directives. This immediate impact on patient recruitment and retention, is now being overshadowed by the opportunities presented to reimagine and reinvigorate studies, to overcome adversary to reap significant benefits now – and in the future. Live: Tuesday, Sept. 29, 2020 at 1pm EDT | 12 pm CDT | 10 am PDT On demand available after airing until Sept. 29, 2021.

Register free: https://www.pharmexec.com/pe_w/impact

Event Overview:

For the past twenty years, sponsors and CROs have been gradually transforming the way they plan and conduct clinical trials with digital technologies to adapt to new realities of doing business in the age of the internet and mobile.

Then COVID-19 hit, resulting in compression of these often decades-long digital transformation roadmaps, as well as, the adoption of new innovation strategies to respond to the realities of shelter-in-place directives. Directives, which have had an immediate impact on the ability to retain and recruit subjects for clinical trials.

This immediate impact is now being overshadowed by the opportunities it presents to reimagine and reinvigorate studies. Drug development models and processes, artificial intelligence/machine learning, decentralized trials, and direct-to-patient services are only some of the options being investigated and deployed.

The stage is set for those sponsors and CROs who are able to accelerate their digital transformation roadmaps and embrace innovative approaches to overcome adversary, to reap significant benefits now – and in the future.

Key Learning Objectives:

In this webcast we will explore:

  • How has the pandemic…?
    • Transformed the clinical trial landscape
    • Accelerated or otherwise alternated digital transformation roadmaps?
    • Led to increased adoption of ICH guidelines
  • What operational shifts needed to occur within sponsors/CROs?
    • How do such changes impact roles and responsibilities?
    • How does this change training plans and other investments sponsors/CROs have made?
  • What technologies have been most impactful?
  • What are some of the obstacles and barriers to this transformation?

Speakers: Julian Jenkins, PhD, Group Vice President, Development Operations & Project Management, Incyte Corporation

Tracy Mayer, Vice President and Global Head, Clinical Data Management and Connected Devices
IQVIA

Richard Wolf, Executive Director, Pv Operations, Global Clinical Safety & Pharmacovigilance, CSL Behring

Sheng Fung, PhD, RWD, Head of APAC, Parexel

Time and date: Live: Tuesday, Sept. 29, 2020 at 1pm EDT | 12 pm CDT | 10 am PDT

On demand available after airing until Sept. 29, 2021.

Sponsor: Oracle Health Sciences

Register free: https://www.pharmexec.com/pe_w/impact

Related Content:

Webcasts